acalabrutinib
astrazeneca
['cll-frail', 'acalabrutinib', 'cll']
acalabrutinib did not display unexpected safety signals in an older, frail population of patients with #cll, according to findings from the ongoing, phase 2 cll-frail trial. #eha2023 
Oncology news and insights from leading researchers and cancer centers.